参考文献/References:
[1] Salcedo I, Tweedie D, Li Y, et al. Neuroprotective and neurotrophic actions of glucagon-like peptide-1: an emerging opportunity to treat neurodegenerative and cerebrovascular disorders[J].Br J Pharmacol,2012,166(5):1586-1599. DOI: 10.1111/j.1476-5381.2012.01971.x.
[2] Akter K, Lanza EA, Martin SA, et al. Diabetes mellitus and Alzheimer's disease: shared pathology and treatment [J].Br J Clin Pharmacol,2011,71(3):365-376. DOI: 10.1111/j.1365-2125.2010.03830.x.
[3] Kappe C, Zhang Q, Nyström T,et al. Effects of high-fat diet and the anti-diabetic drug metformin on circulating GLP-1 and the relative number of intestinal L-cells[J].Diabetol Metab Syndr,2014,6:70.DOI: 10.1186/1758-5996-6-70.
[4] Lovshin JA, Drucker DJ. Incretin-based therapies for type 2 diabetes mellitus[J].Nat Rev Endocrinol,2009,5(5):262-269. DOI: 10.1038/nrendo.2009.48.
[5] Hamilton A, Hölscher C. Receptors for the incretin glucagon-like peptide-1 are expressed on neurons in the central nervous system[J].Neuroreport,2009,20(13):1161-1166.DOI: 10.1097/WNR.0b013e32832fbf14.
[6] Belsham DD, Fick LJ, Dalvi PS, et al. Ciliary neurotrophic factor recruitment of glucagon-like peptide-1 mediates neurogenesis, allowing immortalization of adult murine hypothalamic neurons[J].FASEB J,2009,23(12):4256-4265. DOI: 10.1096/fj.09-133454.
[7] Hamilton A, Patterson S, Porter D,et al. Novel GLP-1 mimetics developed to treat type 2 diabetes promote progenitor cell proliferation in the brain[J].J Neurosci Res,2011,89(4):481-489. DOI: 10.1002/jnr.22565.
[8] Isacson R, Nielsen E, Dannaeus K, et al. The glucagon-like peptide 1 receptor agonist exendin-4 improves reference memory performance and decreases immobility in the forced swim test[J].Eur J Pharmacol,2011,650(1):249-255. DOI: 10.1016/j.ejphar.2010.10.008.
[9] Li H, Lee CH, Yoo KY, et al. Chronic treatment of exendin-4 affects cell proliferation and neuroblast differentiation in the adult mouse hippocampal dentate gyrus[J].Neurosci Lett,2010,486(1):38-42. DOI: 10.1016/j.neulet.2010.09.040.
[10] Luciani P, Deledda C, Benvenuti S,et al. Exendin-4 induces cell adhesion and differentiation and counteracts the invasive potential of human neuroblastoma cells[J].PLoS One,2013,8(8):e71716. DOI: 10.1371/journal.pone.0071716.
[11] McClean PL, Parthsarathy V, Faivre E, et al. The diabetes drug liraglutide prevents degenerative processes in a mouse model of Alzheimer's disease[J].J Neurosci,2011,31(17):6587-6594. DOI: 10.1523/JNEUROSCI.0529-11.2011.
[12] Abbas T, Faivre E, Hölscher C. Impairment of synaptic plasticity and memory formation in GLP-1 receptor KO mice: interaction between type 2 diabetes and Alzheimer's disease[J].Behav Brain Res,2009,205(1):265-271. DOI: 10.1016/j.bbr.2009.06.035.
[13] Li LH, Tian XR, Hu ZP. The key target of neuroprotection after the onset of ischemic stroke: secretory pathway Ca(2+)-ATPase 1[J].Neural Regen Res,2015,10(8):1271-1278. DOI:10.4103/1673-5374.162760.
[14] Bao Y, Jiang L, Chen H,et al. The neuroprotective effect of liraglutide is mediated by glucagon-like peptide 1 receptor-mediated activation of cAMP/PKA/CREB pathway[J].Cell Physiol Biochem,2015,36(6):2366-2378. DOI: 10.1159/000430199.
[15] O'Brien RJ, Wong PC. Amyloid precursor protein processing and Alzheimer's disease[J].Annu Rev Neurosci,2011,34:185-204. DOI: 10.1146/annurev-neuro-061010-113613.
[16] Marchetti C, Marie H. Hippocampal synaptic plasticity in Alzheimer's disease: what have we learned so far from transgenic models [J].Rev Neurosci,2011,22(4):373-402. DOI: 10.1515/RNS.2011.035.
[17] Gengler S, McClean PL, McCurtin R,et al. Val(8)GLP-1 rescues synaptic plasticity and reduces dense core plaques in APP/PS1 mice[J].Neurobiol Aging,2012,33(2):265-276. DOI: 10.1016/j.neurobiolaging.2010.02.014.
[18] Li L, Zhang ZF, Holscher C, et al.(Val )glucagon-like peptide-1 prevents tau hyperphosphorylation, impairment of spatial learning and ultra-structural cellular damage induced by streptozotocin in rat brains[J].Eur J Pharmacol,2012,674(2-3):280-286. DOI: 10.1016/j.ejphar.2011.11.005.
[19] Kim S, Moon M, Park S. Exendin-4 protects dopaminergic neurons by inhibition of microglial activation and matrix metalloproteinase-3expression in an animal model of Parkinson's disease[J].J Endocrinol,2009,202(3):431-439. DOI: 10.1677/JOE-09-0132.
[20] Li Y, Perry T, Kindy MS, et al. GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and parkinsonism[J].Proc Natl Acad Sci U S A,2009,106(4):1285-1290. DOI: 10.1073/pnas.0806720106.
[21] Jolivalt CG, Fineman M, Deacon CF, et al. GLP-1 signals via ERK in peripheral nerve and prevents nerve dysfunction in diabetic mice[J].Diabetes Obes Metab,2011,13(11):990-1000. DOI: 10.1111/j.1463-1326.2011.01431.x.
[22] Kan M, Guo G, Singh B, et al. Glucagon-like peptide 1, insulin, sensory neurons, and diabetic neuropathy[J].J Neuropathol Exp Neurol,2012,71(6):494-510. DOI: 10.1097/NEN.0b013e3182580673.
[23] Martin B, Golden E, Carlson OD, et al. Exendin-4 improves glycemic control, ameliorates brain and pancreatic pathologies, and extends survival in a mouse model of Huntington's disease[J].Diabetes,2009,58(2):318-328. DOI: 10.2337/db08-0799.
[24] Teramoto S, Miyamoto N, Yatomi K,et al. Exendin-4, a glucagon-like peptide-1 receptor agonist, provides neuroprotection in mice transient focal cerebral ischemia[J].J Cereb Blood Flow Metab,2011,31(8):1696-1705. DOI: 10.1038/jcbfm.2011.51.
[25] Liu JH, Yin F, Guo LX,et al. Neuroprotection of geniposide against hydrogen peroxide induced PC12 cells injury: involvement of PI3 kinase signal pathway[J].Acta Pharmacol Sin,2009,30(2):159-165. DOI: 10.1038/aps.2008.25.
[26] Zhang Y, Zhang J, Wang Q, et al. Intravitreal injection of exendin-4 analogue protects retinal cells in early diabetic rats[J].Invest Ophthalmol Vis Sci,2011,52(1):278-285.DOI: 10.1167/iovs.09-4727.
[27] Zhang R, Zhang H, Xu L, et al. Neuroprotective effect of intravitreal cell-based glucagon-like peptide-1 production in the optic nerve crush model[J].Acta Ophthalmol,2011,89(4):e320-e326. DOI: 10.1111/j.1755-3768.2010.02044.x.
相似文献/References:
[1]姚红,郗光霞,郭敏,等.胰高血糖素样肽-1及其受体在中枢神经系统的分布和功能[J].国际内分泌代谢杂志,2014,(01):36.[doi:10.3760/cma.j.issn.1673-4157.2014.01.010]
Yao Hong*,Xi Guangxia,Guo Min,et al.The distributions and functions of glucagon like peptide-1 and its receptors in the central nervous system[J].International Journal of Endocrinology and Metabolism,2014,(05):36.[doi:10.3760/cma.j.issn.1673-4157.2014.01.010]
[2]黄婷婷,沈飞霞,谷雪梅.胰高血糖素样肽-1与骨骼肌葡萄糖代谢[J].国际内分泌代谢杂志,2014,(04):281.[doi:10.3760/cma.j.issn.1673-4157.2014.04.019]
Huang Tingting,Shen Feixia,Gu Xuemei..Glucagon-like peptide-1 and glucose metabolism in the skeletal muscle[J].International Journal of Endocrinology and Metabolism,2014,(05):281.[doi:10.3760/cma.j.issn.1673-4157.2014.04.019]
[3]赵荷珺 洪天配.胰高血糖素样肽-1类药物与胰腺安全性[J].国际内分泌代谢杂志,2015,(05):319.[doi:DOI:10.3760/cma.j.issn.1673-4157.2015.05.008]
Zhao Hejun*,Hong Tianpei..Glucagon-like peptide-1-based therapies and pancreatic safety[J].International Journal of Endocrinology and Metabolism,2015,(05):319.[doi:DOI:10.3760/cma.j.issn.1673-4157.2015.05.008]
[4]齐利琴,刘礼斌.GLP-1在2型糖尿病诱发的阿尔茨海默病治疗中的作用[J].国际内分泌代谢杂志,2016,36(01):48.[doi:10.3760/cma.j.issn.1673-4157.2016.01.012]
Qi Liqin,Liu Libin..Effects of GLP-1 in the treatment of Alzheimer's disease induced by type 2 diabetes mellitus[J].International Journal of Endocrinology and Metabolism,2016,36(05):48.[doi:10.3760/cma.j.issn.1673-4157.2016.01.012]
[5]吴海洋,黄祯子,彭嘉欣,等.胰高血糖素样肽-1与肾素-血管紧张素系统的交互作用[J].国际内分泌代谢杂志,2016,36(05):312.[doi:10.3760/cma.j.issn.1673-4157.2016.05.07]
Wu Haiyang,Huang Zhen-zi,Peng Jiaxin,et al.Interaction between glucagon-like peptide-1 and renin angiotensin system[J].International Journal of Endocrinology and Metabolism,2016,36(05):312.[doi:10.3760/cma.j.issn.1673-4157.2016.05.07]
[6]林楚曼 林伟浩 周蕊 杨力.GLP-1缓解非酒精性脂肪性肝病相关信号通路的研究进展[J].国际内分泌代谢杂志,2018,38(03):179.[doi:10.3760/cma.j.issn.1673-4157.2018.03.009]
Lin Chuman*,Lin Weihao,Zhou Rui,et al.The research progresses on GLP-1 related signal pathways in alleviating non-alcoholic fatty liver disease[J].International Journal of Endocrinology and Metabolism,2018,38(05):179.[doi:10.3760/cma.j.issn.1673-4157.2018.03.009]
[7]阮莹莹 闫彩凤.GLP-1对2型糖尿病患者骨骼的影响[J].国际内分泌代谢杂志,2018,38(04):275.[doi:10.3760/cma.j.issn.1673-4157.2018.04.014]
Ruan Yingying,Yan Caifeng..The impact of GLP-1 on bone in patients with type 2 diabetes[J].International Journal of Endocrinology and Metabolism,2018,38(05):275.[doi:10.3760/cma.j.issn.1673-4157.2018.04.014]
[8]王永 乐岭.GLP-1对血管重构中血管平滑肌细胞的影响[J].国际内分泌代谢杂志,2018,38(01):23.[doi:10.3760/cma.j.issn.1673-4157.2018.01.006]
Wang Yong,Yue Ling.Effects of GLP-1 on vascular smooth muscle cells in vascular remodeling[J].International Journal of Endocrinology and Metabolism,2018,38(05):23.[doi:10.3760/cma.j.issn.1673-4157.2018.01.006]
[9]史雨清,杨昱,李宸,等.Tirzepatide:一种新型GLP-1/GIP双受体激动剂[J].国际内分泌代谢杂志,2021,41(06):645.[doi:10.3760/cma.j.cn121383-20200924-09046]
Shi Yuqing,Yang Yu,Li Chen,et al.Tirzepatide:a novel GLP-1/GIP dual receptor agonist[J].International Journal of Endocrinology and Metabolism,2021,41(05):645.[doi:10.3760/cma.j.cn121383-20200924-09046]